 Vir Biotechnology had obtained about 917.2 million of sotrovimab collaboration revenue in 2021; Expects about 1.1 billion in revenues with all doses delivered by 1st half of 2022. About 95 of patients who took VIR-2218 plus PEG-IFN-a achieved Hepatitis B surface antigen HBsAg levels 100 IUmL. 